JP2017522316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522316A5 JP2017522316A5 JP2017502259A JP2017502259A JP2017522316A5 JP 2017522316 A5 JP2017522316 A5 JP 2017522316A5 JP 2017502259 A JP2017502259 A JP 2017502259A JP 2017502259 A JP2017502259 A JP 2017502259A JP 2017522316 A5 JP2017522316 A5 JP 2017522316A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- antibody
- antigen
- binding fragment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025371P | 2014-07-16 | 2014-07-16 | |
| US62/025,371 | 2014-07-16 | ||
| US201462043167P | 2014-08-28 | 2014-08-28 | |
| US62/043,167 | 2014-08-28 | ||
| US201462080725P | 2014-11-17 | 2014-11-17 | |
| US62/080,725 | 2014-11-17 | ||
| US201562132709P | 2015-03-13 | 2015-03-13 | |
| US62/132,709 | 2015-03-13 | ||
| EP15305830.0 | 2015-05-29 | ||
| EP15305830 | 2015-05-29 | ||
| PCT/US2015/040765 WO2016011260A1 (en) | 2014-07-16 | 2015-07-16 | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522316A JP2017522316A (ja) | 2017-08-10 |
| JP2017522316A5 true JP2017522316A5 (2) | 2018-08-23 |
| JP6912374B2 JP6912374B2 (ja) | 2021-08-04 |
Family
ID=53365943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502259A Active JP6912374B2 (ja) | 2014-07-16 | 2015-07-16 | 高コレステロール血症を有する高心血管リスク患者を処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160137746A1 (2) |
| EP (2) | EP3169362B1 (2) |
| JP (1) | JP6912374B2 (2) |
| KR (3) | KR20240132123A (2) |
| CN (2) | CN114306592A (2) |
| AU (1) | AU2015289617B2 (2) |
| CA (1) | CA2955304C (2) |
| MX (2) | MX378872B (2) |
| PL (1) | PL3169362T3 (2) |
| RU (1) | RU2723018C2 (2) |
| WO (1) | WO2016011260A1 (2) |
| ZA (1) | ZA201700196B (2) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| PL3395836T3 (pl) | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2992345T3 (es) | 2011-09-16 | 2024-12-11 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| MX2016006226A (es) | 2013-11-12 | 2016-09-07 | Sanofi Biotechnology | Regimenes de dosificacion para uso con inhibidores de pcsk9. |
| PL3169353T3 (pl) | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
| EP3197492A1 (en) * | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| JP7541810B2 (ja) | 2016-03-03 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 |
| TW202310872A (zh) * | 2017-06-09 | 2023-03-16 | 法商賽諾菲生物技術公司 | 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法 |
| CA3092936A1 (en) * | 2018-03-06 | 2019-09-12 | Sanofi Biotechnology | Use of pcsk9 inhibitor for reducing cardiovascular risk |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| BR112022009587A2 (pt) * | 2019-11-18 | 2022-08-02 | Ad Pharmaceuticals Co Ltd | Anticorpo anti-pcsk9 e uso do mesmo |
| AU2021320417A1 (en) * | 2020-08-07 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating refractory hypercholesterolemia involving an ANGPTL3 inhibitor |
| CN116983434B (zh) * | 2023-09-28 | 2024-03-15 | 康霖生物科技（杭州）有限公司 | 用于基因治疗的核酸构建体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| PL3395836T3 (pl) * | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
| ES2992345T3 (es) * | 2011-09-16 | 2024-12-11 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| AU2015231713B2 (en) * | 2014-03-17 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Methods for reducing cardiovascular risk |
-
2015
- 2015-07-16 RU RU2017104799A patent/RU2723018C2/ru active
- 2015-07-16 CN CN202111397525.XA patent/CN114306592A/zh active Pending
- 2015-07-16 JP JP2017502259A patent/JP6912374B2/ja active Active
- 2015-07-16 CN CN201580049703.6A patent/CN107106678A/zh active Pending
- 2015-07-16 KR KR1020247028498A patent/KR20240132123A/ko not_active Ceased
- 2015-07-16 MX MX2017000628A patent/MX378872B/es unknown
- 2015-07-16 AU AU2015289617A patent/AU2015289617B2/en active Active
- 2015-07-16 WO PCT/US2015/040765 patent/WO2016011260A1/en not_active Ceased
- 2015-07-16 US US14/801,392 patent/US20160137746A1/en not_active Abandoned
- 2015-07-16 KR KR1020227045465A patent/KR20230007538A/ko not_active Ceased
- 2015-07-16 CA CA2955304A patent/CA2955304C/en active Active
- 2015-07-16 PL PL15760317T patent/PL3169362T3/pl unknown
- 2015-07-16 EP EP15760317.6A patent/EP3169362B1/en active Active
- 2015-07-16 EP EP20174278.0A patent/EP3753575A1/en not_active Withdrawn
- 2015-07-16 KR KR1020177004219A patent/KR102482375B1/ko active Active
-
2017
- 2017-01-10 ZA ZA2017/00196A patent/ZA201700196B/en unknown
- 2017-01-13 MX MX2021000289A patent/MX2021000289A/es unknown
-
2019
- 2019-10-24 US US16/662,313 patent/US20200255544A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522316A5 (2) | ||
| RU2017104799A (ru) | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию | |
| RU2016142277A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| JP2017528427A5 (2) | ||
| JP2016538277A5 (2) | ||
| JP2017031213A5 (2) | ||
| JP2017506626A5 (2) | ||
| US12606638B2 (en) | Dosing regimens for use with PCSK9 inhibitors | |
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| US20220144969A1 (en) | Methods for reducing cardiovascular risk | |
| JP7744190B2 (ja) | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 | |
| ES2914978T3 (es) | Uso de un inhibidor de PCSK9 para tratar hiperlipidemia | |
| ES2773111T3 (es) | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) | |
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2013023499A5 (2) | ||
| JP2016538248A5 (2) | ||
| JP2022177142A5 (2) | ||
| JP2019514907A5 (2) | ||
| JP2019509988A5 (2) | ||
| JP2015187125A5 (2) | ||
| RU2013156848A (ru) | Лечение антителами против pcsk9 | |
| Liu et al. | A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis | |
| KR20190014117A (ko) | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 | |
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| JP2014511361A5 (2) |